Combination Chemotherapy in Treating Patients With Lymphoma
Public ClinicalTrials.gov record NCT00002835. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma
Study identification
- NCT ID
- NCT00002835
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 116 participants
Conditions and interventions
Conditions
Interventions
- Bleomycin Sulfate (BLM) Biological
- Carmustine Drug
- Cisplatin (CDDP) Drug
- Cyclophosphamide Drug
- Cytarabine (ARA-C) Drug
- Etoposide (VP-16) Drug
- Filgrastim (G-CSF) Biological
- Idarubicin Drug
- Ifosfamide Drug
- Leucovorin Calcium Drug
- Melphalan Drug
- Methotrexate Drug
- Methylprednisolone Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Radiation Therapy Radiation
- Recombinant Interferon Alfa Biological
- Vincristine Sulfate Drug
- mitoxantrone hydrochloride (DHAD) Drug
Biological · Drug · Procedure + 1 more
Eligibility (public fields only)
- Age range
- 15 Years to 59 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 1995
- Primary completion
- Feb 3, 2004
- Completion
- Feb 3, 2004
- Last update posted
- Nov 14, 2018
1995 – 2004
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00002835, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2018 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00002835 live on ClinicalTrials.gov.